logo

For the Inventor, By the Inventor

San Jose, CA, United States of America

Ariosa Diagnostics, Inc.


USPTO Granted Patents = 27



Trademarks = 8

Forward Citations = 157

Loading Chart...
Loading Chart...

13 inventors (with patents filed for the assignee):

goldMedal Arnold Oliphant (23 out of 49 patents)

silverMedal Craig Struble (14 out of 22 patents)

bronzeMedal Andrew Sparks (14 out of 21 patents)

4.  John Stuelpnagel (13 out of 16 patents)

5.  Jacob Zahn (10 out of 12 patents)

6.  Ken Song (9 out of 10 patents)

7.  Eric Wang (6 out of 17 patents)

8.  Eric Wang (4 out of 14 patents)

9.  Patrick Bogard (3 out of 4 patents)

10.  Stephanie Huang (3 out of 4 patents)

11.  Kara Juneau (2 out of 3 patents)

12.  Morassa Mohseni (2 out of 2 patents)

13.  Kara Jeneau (1 out of 1 patent)


Core Competencies:
Fetal Aneuploidy
Genetic Analysis
Copy Number Variation
Hybridization
Risk Calculation
Nucleic Acids
Statistical Analysis
Genetic Variants
Non-Invasive Testing
Sex Determination
Assay Systems
Biomolecule Estimations

27 patents:

1. 12195799 - Risk calculation for evaluation of fetal aneuploidy (2025-01-14),
2. 11299772 - Assay systems for genetic analysis (2022-04-12),
3. 11289176 - Determination of copy number variations using binomial probability calculations (2022-03-29),
4. 11270781 - Statistical analysis for non-invasive sex chromosome aneuploidy determination (2022-03-08),
5. 11203786 - Detection of target nucleic acids using hybridization (2021-12-21),
6. 11091807 - Assay systems for genetic analysis (2021-08-17),
7. 11031095 - Assay systems for determination of fetal copy number variation (2021-06-08),
8. 10954566 - Ligation-based detection of genetic variants (2021-03-23),
9. 10907198 - Assay systems for genetic analysis (2021-02-02),
10. 10847250 - Determination of copy number variations using binomial probability calculations (2020-11-24),
11. 10718024 - Risk calculation for evaluation of fetal aneuploidy (2020-07-21),
12. 10718019 - Risk calculation for evaluation of fetal aneuploidy (2020-07-21),
13. 10533223 - Detection of target nucleic acids using hybridization (2020-01-14),
14. 10308981 - Assay systems for determination of source contribution in a sample (2019-06-04),
15. 10289800 - Processes for calculating phased fetal genomic sequences (2019-05-14),
Company Overview
Ariosa Diagnostics, Inc. is a biotechnology company based in San Jose, California, specializing in non-invasive prenatal testing solutions. The organization focuses on developing advanced diagnostic technologies that leverage genetic analysis to provide critical insights into fetal health. By utilizing proprietary methodologies, Ariosa aims to enhance prenatal care and improve outcomes for expectant parents. Their innovative approach positions them at the forefront of the evolving landscape of reproductive health diagnostics.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

Ariosa Diagnostics, Inc. USPTO Patent Assignee Logo
27 Patents

#279 in San Jose, CA

#2,931 in California

#12,410 in US

#23,984 in the World

San Jose, CA (US)
San Jose, CA, United States of America

Ariosa Diagnostics, Inc.

Forward Citations = 157

13 inventors:

goldMedal Arnold Oliphant (23 out of 49 patents)

silverMedal Craig Struble (14 out of 22 patents)

bronzeMedal Andrew Sparks (14 out of 21 patents)

4.  John Stuelpnagel (13 out of 16 patents)

5.  Jacob Zahn (10 out of 12 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Ariosa Diagnostics, Inc.. Retrieved from https://idiyas.com/company/ariosa-diagnostics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…